BioLineRx In-licenses Novel Anti-Inflammatory Treatment for Dry Eye Syndrome Under Strategic Collaboration with Major Global Pharmaceutical Company
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 10/23/2026
- Wall St dips after AI-led selloff; SpaceX worries hit telecoms
- Meta's capital-raising plans expose a major weakness in the AI boom
- Brent crude hits more than five-month high on Houthi-Saudi attacks, UAE oil spill
- BofA flags further downside risk for stocks, yields and dollar
- SpaceX cell-site ambitions lift tower stocks and weigh on carriers
| Bioline RX Ltd Ordinary shares (AMEX: BLNEF) | Delayed: 0.86 --0 (-0%) | |||||
|---|---|---|---|---|---|---|
| Previous Close | $0.86 | 52 Week High | $1.54 | |||
| Open | $1.64 | 52 Week Low | $1.15 | |||
| Day High | $0.86 | P/E | N/A | |||
| Day Low | $0.86 | EPS | $0.00 | |||
| Volume | 1,500 | |||||
| Bioline RX Ltd Ordinary shares (AMEX: BLNEF) | Delayed: 0.86 --0 (-0%) | |||||
|---|---|---|---|---|---|---|
| Previous Close | $0.86 | 52 Week High | $1.54 | |||
| Open | $1.64 | 52 Week Low | $1.15 | |||
| Day High | $0.86 | P/E | N/A | |||
| Day Low | $0.86 | EPS | $0.00 | |||
| Volume | 1,500 | |||||
| BIOLINE RX SP ADR (NASDAQ: BLRX) | Delayed: 2.11 +0.05 (2.43%) | |||||
|---|---|---|---|---|---|---|
| Previous Close | $2.06 | 52 Week High | $1.63 | |||
| Open | $2.04 | 52 Week Low | $0.71 | |||
| Day High | $2.11 | P/E | N/A | |||
| Day Low | $2.04 | EPS | $0.00 | |||
| Volume | 864 | |||||
| BIOLINE RX SP ADR (NASDAQ: BLRX) | Delayed: 2.11 +0.05 (2.43%) | |||||
|---|---|---|---|---|---|---|
| Previous Close | $2.06 | 52 Week High | $1.63 | |||
| Open | $2.04 | 52 Week Low | $0.71 | |||
| Day High | $2.11 | P/E | N/A | |||
| Day Low | $2.04 | EPS | $0.00 | |||
| Volume | 864 | |||||
